Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Notes Payables (2021 - 2024)

Actinium Pharmaceuticals (ATNM) has disclosed Notes Payables for 6 consecutive years, with $7.5 million as the latest value for Q1 2024.

  • Quarterly Notes Payables rose 2.11% to $7.5 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Mar 2024, up 2.11% year-over-year, with the annual reading at $8.0 million for FY2023, 21.49% down from the prior year.
  • Notes Payables for Q1 2024 was $7.5 million at Actinium Pharmaceuticals, down from $8.0 million in the prior quarter.
  • The five-year high for Notes Payables was $10.1 million in Q4 2022, with the low at $3.4 million in Q2 2021.
  • Average Notes Payables over 4 years is $6.5 million, with a median of $7.4 million recorded in 2023.
  • The sharpest move saw Notes Payables soared 108.56% in 2022, then decreased 21.49% in 2023.
  • Over 4 years, Notes Payables stood at $5.5 million in 2021, then surged by 83.02% to $10.1 million in 2022, then decreased by 21.49% to $8.0 million in 2023, then fell by 5.53% to $7.5 million in 2024.
  • According to Business Quant data, Notes Payables over the past three periods came in at $7.5 million, $8.0 million, and $8.2 million for Q1 2024, Q4 2023, and Q3 2023 respectively.